Cargando…

The Survival of Patients with t(15;17)(q22;q12) Positive Acute Promyelocytic Leukemia: A Study in North-East of Iran

BACKGROUND & OBJECTIVE: Acute promyelocytic leukemia (APL) with t(15;17)(q22;q12) is a relatively common subtype of acute myeloid leukemia (AML). Here, our objective was to ascertain the survival of patients with this leukemia in north-east of Iran. METHODS: Survival rates of 42 APL patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Ayatollahi, Hossein, Bazi, Ali, Sadeghian, Mohammad Hadi, Fani, Ali, Siyadat, Payam, Sheikhi, Maryam, Sargazi-aval, Omolbanin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Iranian Society of Pathology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354063/
https://www.ncbi.nlm.nih.gov/pubmed/32754212
http://dx.doi.org/10.30699/ijp.2020.101417.2007
_version_ 1783558006173073408
author Ayatollahi, Hossein
Bazi, Ali
Sadeghian, Mohammad Hadi
Fani, Ali
Siyadat, Payam
Sheikhi, Maryam
Sargazi-aval, Omolbanin
author_facet Ayatollahi, Hossein
Bazi, Ali
Sadeghian, Mohammad Hadi
Fani, Ali
Siyadat, Payam
Sheikhi, Maryam
Sargazi-aval, Omolbanin
author_sort Ayatollahi, Hossein
collection PubMed
description BACKGROUND & OBJECTIVE: Acute promyelocytic leukemia (APL) with t(15;17)(q22;q12) is a relatively common subtype of acute myeloid leukemia (AML). Here, our objective was to ascertain the survival of patients with this leukemia in north-east of Iran. METHODS: Survival rates of 42 APL patients with t(15;17)(q22;q12) were assessed. Clinical information was obtained from archived medical records. Statistical analysis was performed by SPSS 18 software using log-ranked test and Kaplan Maier survival analysis. RESULTS: Females and males comprised 49% and 51%, respectively. The mean age at diagnosis was 34.3 [Formula: see text] 14.1 years old. During the study period, 17 demises occurred in males, while this number was 7 in females. The mean survival of patients (month) was 23.22 [Formula: see text] 3.57 (95% CI: 16.21 [Formula: see text] 30.2). The five-year survival rate obtained 30%. Regarding demographic and clinical features, the highest rates of 5-year survival were recorded in patients with 20-35 years old (47.6%), males (51%), white blood cell count <10 [Formula: see text] /l (48%), and platelet count >140 [Formula: see text] /l (100%). CONCLUSION: Younger age, lower WBC count and higher platelet count were significantly associated with longer survival in AML patients with t(15;17)(q22; q12).
format Online
Article
Text
id pubmed-7354063
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Iranian Society of Pathology
record_format MEDLINE/PubMed
spelling pubmed-73540632020-08-03 The Survival of Patients with t(15;17)(q22;q12) Positive Acute Promyelocytic Leukemia: A Study in North-East of Iran Ayatollahi, Hossein Bazi, Ali Sadeghian, Mohammad Hadi Fani, Ali Siyadat, Payam Sheikhi, Maryam Sargazi-aval, Omolbanin Iran J Pathol Original Article BACKGROUND & OBJECTIVE: Acute promyelocytic leukemia (APL) with t(15;17)(q22;q12) is a relatively common subtype of acute myeloid leukemia (AML). Here, our objective was to ascertain the survival of patients with this leukemia in north-east of Iran. METHODS: Survival rates of 42 APL patients with t(15;17)(q22;q12) were assessed. Clinical information was obtained from archived medical records. Statistical analysis was performed by SPSS 18 software using log-ranked test and Kaplan Maier survival analysis. RESULTS: Females and males comprised 49% and 51%, respectively. The mean age at diagnosis was 34.3 [Formula: see text] 14.1 years old. During the study period, 17 demises occurred in males, while this number was 7 in females. The mean survival of patients (month) was 23.22 [Formula: see text] 3.57 (95% CI: 16.21 [Formula: see text] 30.2). The five-year survival rate obtained 30%. Regarding demographic and clinical features, the highest rates of 5-year survival were recorded in patients with 20-35 years old (47.6%), males (51%), white blood cell count <10 [Formula: see text] /l (48%), and platelet count >140 [Formula: see text] /l (100%). CONCLUSION: Younger age, lower WBC count and higher platelet count were significantly associated with longer survival in AML patients with t(15;17)(q22; q12). Iranian Society of Pathology 2020 2020-04-21 /pmc/articles/PMC7354063/ /pubmed/32754212 http://dx.doi.org/10.30699/ijp.2020.101417.2007 Text en This is an open-access article distributed under the terms of the Creative Commons Attribution-noncommercial 4.0 International License, (https://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
spellingShingle Original Article
Ayatollahi, Hossein
Bazi, Ali
Sadeghian, Mohammad Hadi
Fani, Ali
Siyadat, Payam
Sheikhi, Maryam
Sargazi-aval, Omolbanin
The Survival of Patients with t(15;17)(q22;q12) Positive Acute Promyelocytic Leukemia: A Study in North-East of Iran
title The Survival of Patients with t(15;17)(q22;q12) Positive Acute Promyelocytic Leukemia: A Study in North-East of Iran
title_full The Survival of Patients with t(15;17)(q22;q12) Positive Acute Promyelocytic Leukemia: A Study in North-East of Iran
title_fullStr The Survival of Patients with t(15;17)(q22;q12) Positive Acute Promyelocytic Leukemia: A Study in North-East of Iran
title_full_unstemmed The Survival of Patients with t(15;17)(q22;q12) Positive Acute Promyelocytic Leukemia: A Study in North-East of Iran
title_short The Survival of Patients with t(15;17)(q22;q12) Positive Acute Promyelocytic Leukemia: A Study in North-East of Iran
title_sort survival of patients with t(15;17)(q22;q12) positive acute promyelocytic leukemia: a study in north-east of iran
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354063/
https://www.ncbi.nlm.nih.gov/pubmed/32754212
http://dx.doi.org/10.30699/ijp.2020.101417.2007
work_keys_str_mv AT ayatollahihossein thesurvivalofpatientswitht1517q22q12positiveacutepromyelocyticleukemiaastudyinnortheastofiran
AT baziali thesurvivalofpatientswitht1517q22q12positiveacutepromyelocyticleukemiaastudyinnortheastofiran
AT sadeghianmohammadhadi thesurvivalofpatientswitht1517q22q12positiveacutepromyelocyticleukemiaastudyinnortheastofiran
AT faniali thesurvivalofpatientswitht1517q22q12positiveacutepromyelocyticleukemiaastudyinnortheastofiran
AT siyadatpayam thesurvivalofpatientswitht1517q22q12positiveacutepromyelocyticleukemiaastudyinnortheastofiran
AT sheikhimaryam thesurvivalofpatientswitht1517q22q12positiveacutepromyelocyticleukemiaastudyinnortheastofiran
AT sargaziavalomolbanin thesurvivalofpatientswitht1517q22q12positiveacutepromyelocyticleukemiaastudyinnortheastofiran
AT ayatollahihossein survivalofpatientswitht1517q22q12positiveacutepromyelocyticleukemiaastudyinnortheastofiran
AT baziali survivalofpatientswitht1517q22q12positiveacutepromyelocyticleukemiaastudyinnortheastofiran
AT sadeghianmohammadhadi survivalofpatientswitht1517q22q12positiveacutepromyelocyticleukemiaastudyinnortheastofiran
AT faniali survivalofpatientswitht1517q22q12positiveacutepromyelocyticleukemiaastudyinnortheastofiran
AT siyadatpayam survivalofpatientswitht1517q22q12positiveacutepromyelocyticleukemiaastudyinnortheastofiran
AT sheikhimaryam survivalofpatientswitht1517q22q12positiveacutepromyelocyticleukemiaastudyinnortheastofiran
AT sargaziavalomolbanin survivalofpatientswitht1517q22q12positiveacutepromyelocyticleukemiaastudyinnortheastofiran